ESC Professional Premium Access

The effect of achieving LDL-C <1.8 mmol/L to prevent the first atherosclerotic cardiovascular events in the primary prevention settings of severe heterozygous familial hypercholesterolemia

Congress Presentation

About the speaker

Doctor Sayaka Funabashi

National Cerebral and Cardiovascular Center Hospital, Osaka (Japan)
1 follower

5 more presentations in this session

Effect of evolocumab versus placebo added to standard lipid-lowering therapy on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia

Speaker: Ms B. Heidemann (Utrecht, NL)


Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial

Speaker: Doctor A. Sharma (Montreal, CA)


Icosapent Ethyl diminishes CVD risk in smokers: REDUCE-IT smoking

Speaker: Professor M. Miller (Philadelphia, US)


Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia

Speaker: Doctor A. Wiegman (Amsterdam, NL)


Clinical consequences of the lipid-lowering treatment in patients with acute coronary syndrome: real-world retrospective study (LipidACS study)

Speaker: Doctor J. Alarcon (Donostia, ES)


Access the full session

Optimal risk factor therapy in high risk patients

Speakers: Doctor S. Funabashi, Ms B. Heidemann, Doctor A. Sharma, Professor M. Miller, Doctor A. Wiegman...

About the event


ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk